RxDoctor Payments Data

Kelli Bremer

Psychiatry · Lincoln, NENPI 1902894082

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 71.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $6,458 and has fallen 77.8% since, to $1,434 in 2025. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,597in general payments, 2019–2025

Across 466 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Lundbeck LLC$2K
  • Otsuka America Pharmaceutical, Inc.$633
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$465
  • Johnson & Johnson$232
  • Takeda Pharmaceuticals U.S.A., Inc.$200
  • plus $365 from 6 others

What the payments were for

  • Speaking & faculty fees$6,05048%
  • Travel & lodging$1371%
  • Food & beverage$6,41051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,597 in reported general payments places this provider in the 90th percentile of 160 psychiatry providers in Nebraska.

See all psychiatry providers in Nebraska

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate15$5,937
Aripiprazole13$2,062
Desvenlafaxine Succinate ErDesvenlafaxine Succinate32$1,655
Vilazodone Hcl18$1,456
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$1,341
Clozapine13$1,291
Lamotrigine92$742
Bupropion XlBupropion Hcl37$610
Trazodone Hcl40$593
Clonazepam44$477
Duloxetine Hcl15$462
Sertraline Hcl32$447
Fluoxetine Hcl19$367
Bupropion Hcl SrBupropion Hcl15$355
Quetiapine Fumarate27$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$200$5,93715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 psychiatry providers in Nebraska.

Other psychiatry in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →